These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 33119450

  • 21. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M, Yeaw J, Divino V, DeKoven M, Guerrero G, Langer J, Thorsted BL.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [Abstract] [Full Text] [Related]

  • 22. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 23. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA, Baron MA, Gao L, Blonde L.
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [Abstract] [Full Text] [Related]

  • 24. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J, Divino V, Burudpakdee C.
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [Abstract] [Full Text] [Related]

  • 25. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.
    Kostev K, Dippel FW, Rathmann W.
    Prim Care Diabetes; 2016 Apr; 10(2):142-7. PubMed ID: 26324105
    [Abstract] [Full Text] [Related]

  • 26. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D, Lee TA, Schumock GT, Walton SM, Gerber BS, Nutescu EA, Touchette DR.
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A.
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [Abstract] [Full Text] [Related]

  • 28. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents.
    Kalsekar ID, Madhavan SS, Amonkar MM, Makela EH, Scott VG, Douglas SM, Elswick BL.
    Ann Pharmacother; 2006 Apr; 40(4):605-11. PubMed ID: 16551768
    [Abstract] [Full Text] [Related]

  • 29. Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization.
    Sun P, Lian J.
    Postgrad Med; 2016 May; 128(4):338-45. PubMed ID: 26849064
    [Abstract] [Full Text] [Related]

  • 30. Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris.
    Tan X, Al-Dabagh A, Davis SA, Lin HC, Balkrishnan R, Chang J, Feldman SR.
    Am J Clin Dermatol; 2013 Jun; 14(3):243-51. PubMed ID: 23572294
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [Abstract] [Full Text] [Related]

  • 32. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.
    Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System.
    Benedict AW, Spence MM, Sie JL, Chin HA, Ngo CD, Salmingo JF, Vidaurreta AT, Rashid N.
    J Manag Care Spec Pharm; 2018 Feb; 24(2):114-122. PubMed ID: 29384029
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
    Grabner M, Chu J, Raparla S, Quimbo R, Zhou S, Conoshenti J.
    Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
    [Abstract] [Full Text] [Related]

  • 38. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.
    Toyoda M, Kimura M, Yamamoto N, Miyauchi M, Umezono T, Suzuki D.
    J Nephrol; 2012 May; 25(6):989-95. PubMed ID: 22307438
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.